Learn more about our methodology and business model here
Seven peptides are on the July 23-24, 2026 agenda for section 503A review: BPC-157, KPV, TB-500, and MOTS-C on July 23, and Emideltide (DSIP), Semax, and Epitalon on July 24
Citing significant, unresolved safety risks, a total lack of robust human clinical efficacy data, and grave concerns over immunogenicity and peptide-related impurities, the FDA officially designated 19 of the most popular therapeutic peptidesexplicitly including BPC-157, TB-500 (Thymosin beta-4 fragment), and injectable GHK-Cuas Category 2 bulk drug substances
Stress also depletes glutathione levels, and low glutathione has been linked to every major aging process in the body